ALGS Aligos Therapeutics Inc
Price (delayed)
$10.81
Market cap
$66.1M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$20.94
Enterprise value
$37.36M
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver
Highlights
The company's debt fell by 25% YoY and by 8% QoQ
Aligos Therapeutics's EPS has plunged by 182% from the previous quarter but it has increased by 39% YoY
Aligos Therapeutics's equity has shrunk by 158% QoQ and by 131% YoY
ALGS's gross profit has dropped by 75% year-on-year and by 34% since the previous quarter
Key stats
What are the main financial stats of ALGS
Market
Valuations
Earnings
Shares outstanding
6.11M
Market cap
$66.1M
Enterprise value
$37.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
17.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.47
Revenue
$3.95M
Gross profit
$3.95M
Operating income
-$89.15M
Net income
-$131.21M
EBIT
-$135.29M
EBITDA
-$132.66M
Free cash flow
-$80.87M
Per share
Balance sheet
Liquidity
EPS
-$20.94
EPS diluted
-$20.94
Free cash flow per share
-$12.91
Book value per share
-$8.08
Revenue per share
$0.63
TBVPS
$11.19
Total assets
$70.09M
Total liabilities
$99.07M
Debt
$8.38M
Equity
-$28.97M
Working capital
$40.4M
Debt to equity
-0.29
Current ratio
2.86
Quick ratio
2.62
Net debt/EBITDA
0.22
Margins
Efficiency
Dividend
EBITDA margin
-3,362.8%
Gross margin
100%
Net margin
-3,326%
Operating margin
-2,259.9%
Return on assets
-132.8%
Return on equity
-354.3%
Return on invested capital
-262.9%
Return on capital employed
-279.8%
Return on sales
-3,429.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALGS stock price
How has the Aligos Therapeutics stock price performed over time
Intraday
2.85%
1 week
-24.93%
1 month
-48.55%
1 year
-50.3%
YTD
-72.87%
QTD
-72.87%
Financial performance
How have Aligos Therapeutics's revenue and profit performed over time
Revenue
$3.95M
Gross profit
$3.95M
Operating income
-$89.15M
Net income
-$131.21M
Gross margin
100%
Net margin
-3,326%
The company's net margin has shrunk by 159% QoQ
ALGS's gross profit has dropped by 75% year-on-year and by 34% since the previous quarter
ALGS's revenue has dropped by 75% year-on-year and by 34% since the previous quarter
Aligos Therapeutics's net income has shrunk by 71% QoQ and by 50% YoY
Growth
What is Aligos Therapeutics's growth rate over time
Valuation
What is Aligos Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
17.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.47
Aligos Therapeutics's EPS has plunged by 182% from the previous quarter but it has increased by 39% YoY
Aligos Therapeutics's equity has shrunk by 158% QoQ and by 131% YoY
The stock's price to sales (P/S) is 83% less than its 5-year quarterly average of 103.1 and 24% less than its last 4 quarters average of 22.6
ALGS's revenue has dropped by 75% year-on-year and by 34% since the previous quarter
Efficiency
How efficient is Aligos Therapeutics business performance
Aligos Therapeutics's ROS has plunged by 113% from the previous quarter
ALGS's return on assets has dropped by 106% since the previous quarter and by 76% year-on-year
The company's return on invested capital has surged by 75% YoY but it fell by 29% QoQ
Dividends
What is ALGS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALGS.
Financial health
How did Aligos Therapeutics financials performed over time
The total assets is 29% less than the total liabilities
The total liabilities has surged by 158% since the previous quarter and by 67% year-on-year
ALGS's quick ratio has dropped by 54% year-on-year and by 27% since the previous quarter
The company's debt is 129% higher than its equity
Aligos Therapeutics's equity has shrunk by 158% QoQ and by 131% YoY
The company's debt fell by 25% YoY and by 8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.